An interesting article ran yesterday in the New York Business Journal by Chris Rauber. Referencing the recent announcement that UnitedHealth Group, citing disappointing financial results, could possibly withdraw from the Obamacare market, Mr. Rauber questions the financial viability of the new underwriting rules and warns of the potential for ACA Marketplace "death spiral".
Meanwhile, I have yet to find an individual who bought a full priced plan (without a subsidy) on the exchange and found it to be a good value. If the insured aren't getting their money's worth and the insurers are not making a profit, the scheme will surely fail regardless of federal law and the various intimidation tactics being deployed to force insurers and beneficiaries to participate.
Tuesday, November 10, 2015
CNNMoney, in an 11.06.15 post, reports:
Lilly (LLY), based in Indianapolis, said it is being asked about "our treatment of certain distribution service agreements with wholesalers," and how that affects the price it is allowed to charge Medicaid.
New Jersey-based Merck (MRK) said it has been asked for documents related to its "contracting and pricing of Dulera Inhalation Aerosol with...Medicare Part D [drug] plans."
Read more in the current issue of Week in Review>> http://conta.cc/1klcQHS